

Effective Date: 01/01/2019
Reviewed: 02/2019, 4/2020, 1/2021, 1/2022, 1/2023
Scope: Medicaid

Diacomit (Stiripentol)

POLICY

I. CRITERIA FOR APPROVAL

An authorization of 12 weeks may be granted when all the following criteria are met:

- A. Patient has a diagnosis of Dravet syndrome and the diagnosis has been confirmed by two unaffiliated neurologists/epileptologists
- B. Medication is being prescribed by a neurologist or epileptologist
- C. Patient is 2 years of age and older
- D. Patient is currently taking clobazam
- E. Baseline neutrophil and platelet count be obtained prior to starting treatment

II. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members who are tolerating treatment and has had a 50% reduction in frequency per 30 days of generalized clonic or tonic-clonic seizures

III. QUANTITY LIMIT

Diacomit 250mg: 180 caps per 30 days

Diacomit 500mg : 180 caps per 30 days